

Michael S Sabel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2019487/publications.pdf>

Version: 2024-02-01

175
papers

14,175
citations

23567

58
h-index

20358

116
g-index

181
all docs

181
docs citations

181
times ranked

17942
citing authors

#	ARTICLE	IF	CITATIONS
1	A single institution's review of patterns of compliance with melanoma ultrasound surveillance recommendations. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 207-208.	1.2	0
2	Genomic Expression Profiling in Melanoma and the Road to Clinical Practice. <i>Annals of Surgical Oncology</i> , 2022, 29, 764-766.	1.5	3
3	Factors associated with disease-free and abdominal recurrence-free survival in abdominopelvic and retroperitoneal sarcomas. <i>Journal of Surgical Oncology</i> , 2022, 125, 1292-1300.	1.7	5
4	Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis. <i>Journal of Surgical Oncology</i> , 2022, 125, 1218-1223.	1.7	2
5	Trends in Breast Cancer Treatment De-Implementation in Older Patients with Hormone Receptor-Positive Breast Cancer: A Mixed Methods Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 902-913.	1.5	19
6	Chemotherapy-Induced Peripheral Neuropathy Detection via a Smartphone App: Cross-sectional Pilot Study. <i>JMIR MHealth and UHealth</i> , 2021, 9, e27502.	3.7	4
7	Introduction: Immuno-oncology seminar. <i>Journal of Surgical Oncology</i> , 2021, 123, 708-709.	1.7	0
8	Immunotherapy for Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 775-781.	1.7	17
9	Disclosure slide at the Society of Surgical Oncology Annual Symposium "Is there room for improvement?". <i>Journal of Surgical Oncology</i> , 2021, 123, 1677-1678.	1.7	0
10	Impact of Breast Cancer Pretreatment Nodal Burden and Disease Subtype on Axillary Surgical Management. <i>Journal of Surgical Research</i> , 2021, 261, 67-73.	1.6	2
11	ASO Visual Abstract: Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer "3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial. <i>Annals of Surgical Oncology</i> , 2021, 28, 628-629.	1.5	0
12	Cryoablation Without Excision for Low-Risk Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial. <i>Annals of Surgical Oncology</i> , 2021, 28, 5525-5534.	1.5	43
13	A Framework for De-implementation in Surgery. <i>Annals of Surgery</i> , 2021, 273, e105-e107.	4.2	5
14	Opioid prescribing exceeds consumption following common surgical oncology procedures. <i>Journal of Surgical Oncology</i> , 2021, 123, 352-356.	1.7	3
15	CX3CR1 ^{hi} CD8 ⁺ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. <i>JCI Insight</i> , 2020, 5, .	5.0	48
16	Integration of Breast Reconstruction and Postmastectomy Radiotherapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 2329-2340.	1.6	27
17	Clinical Cancer Advances 2020: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2020, 38, 1081.	1.6	101
18	Maintenance of Certification and Continuing Medical Education: Are They Still Required?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3820-3823.	1.5	4

#	ARTICLE	IF	CITATIONS
19	Axillary Pathologic Complete Response in Inflammatory Breast Cancer Patients: Implications for SLNB?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3374-3379.	1.5	7
20	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	1.6	66
21	The Impact of Education and Prescribing Guidelines on Opioid Prescribing for Breast and Melanoma Procedures. <i>Annals of Surgical Oncology</i> , 2019, 26, 17-24.	1.5	60
22	In reply: Management of thin melanoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 536-536.	1.7	0
23	Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 659-666.	1.6	40
24	Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1317-1322.	1.6	60
25	Association of B7-H4, PD-L1, and tumor infiltrating lymphocytes with outcomes in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 40.	5.2	36
26	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
27	Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. <i>Cell Metabolism</i> , 2018, 28, 87-103.e6.	16.2	263
28	Pleomorphic Lobular Carcinoma In Situ: Imaging Features, Upgrade Rate, and Clinical Outcomes. <i>American Journal of Roentgenology</i> , 2018, 211, 462-467.	2.2	19
29	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	1.6	318
30	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	27.0	1,087
31	Study protocol: A randomized controlled trial of a comprehensive breast cancer treatment patient decision tool (iCanDecide). <i>Contemporary Clinical Trials Communications</i> , 2017, 5, 123-132.	1.1	4
32	Dorsal Muscle Attenuation May Predict Failure to Respond to Interleukin-2 Therapy in Metastatic Renal Cell Carcinoma. <i>Academic Radiology</i> , 2017, 24, 1094-1100.	2.5	6
33	The natural history of thin melanoma and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2017, 116, 1185-1192.	1.7	18
34	Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 665-670.	1.7	5
35	Surgeon and Radiation Oncologist Views on Omission of Adjuvant Radiotherapy for Older Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2017, 24, 3518-3526.	1.5	36
36	In vivo near-infrared imaging of ErbB2 expressing breast tumors with dual-axes confocal endomicroscopy using a targeted peptide. <i>Scientific Reports</i> , 2017, 7, 14404.	3.3	10

#	ARTICLE	IF	CITATIONS
37	Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. <i>Cancer Research</i> , 2016, 76, 3156-3165.	0.9	224
38	Trends in Media Reports of Celebrities™ Breast Cancer Treatment Decisions. <i>Annals of Surgical Oncology</i> , 2016, 23, 2795-2801.	1.5	16
39	Differences between Breast Conservation-Eligible Patients and Unilateral Mastectomy Patients in Choosing Contralateral Prophylactic Mastectomies. <i>Breast Journal</i> , 2016, 22, 607-615.	1.0	17
40	An Analysis of the Decisions Made for Contralateral Prophylactic Mastectomy and Breast Reconstruction. <i>Plastic and Reconstructive Surgery</i> , 2016, 138, 29-40.	1.4	39
41	A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072. <i>Annals of Surgical Oncology</i> , 2016, 23, 2438-2445.	1.5	95
42	Morphomics predicts response to ipilimumab in patients with stage IV melanoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 333-337.	1.7	14
43	Sentinel Lymph Node Biopsy Use Among Melanoma Patients 75 Years of Age and Older. <i>Annals of Surgical Oncology</i> , 2015, 22, 2112-2119.	1.5	26
44	Defining the Relationship between Patient Decisions to Undergo Breast Reconstruction and Contralateral Prophylactic Mastectomy. <i>Plastic and Reconstructive Surgery</i> , 2015, 135, 661-670.	1.4	53
45	Lobular Neoplasia: Morphology and Management. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 1344-1349.	2.5	23
46	EZH2 expands breast stem cells through activation of NOTCH1 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3098-3103.	7.1	170
47	International Multi-institutional Management and Outcome of Melanoma Patients with Positive Sentinel Lymph Nodes in More than One Nodal Basin. <i>Annals of Surgical Oncology</i> , 2014, 21, 4324-4329.	1.5	13
48	Is Intraoperative Frozen Section Analysis of Reexcision Specimens of Value in Preventing Reoperation in Breast-Conserving Therapy?. <i>American Journal of Clinical Pathology</i> , 2014, 142, 601-608.	0.7	25
49	Nonsurgical Ablation of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2014, 23, 593-608.	1.5	21
50	Discordance in Histopathologic Evaluation of Melanoma Sentinel Lymph Node Biopsy with Clinical Follow-Up: Results from a Prospectively Collected Database. <i>Annals of Surgical Oncology</i> , 2014, 21, 3406-3411.	1.5	7
51	Individualized, Patient-Centered Application of Consensus Guidelines to Improve the Quality of Breast Cancer Care. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 535-536.	0.8	12
52	Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. <i>Blood</i> , 2014, 123, 1487-1498.	1.4	154
53	A Rising Trend in Use of Contralateral Prophylactic Mastectomy. <i>Plastic and Reconstructive Surgery</i> , 2014, 134, 87.	1.4	2
54	Analytic morphometric assessment of patients undergoing colectomy for colon cancer. <i>Journal of Surgical Oncology</i> , 2013, 108, 169-175.	1.7	69

#	ARTICLE	IF	CITATIONS
55	Surgeons' Knowledge and Practices Regarding the Role of Radiation Therapy in Breast Cancer Management. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1022-1029.	0.8	14
56	The Need for Axillary Lymph Node Dissection in T1/T2 Breast Cancer Surgeryâ€”Counterpoint. Cancer Research, 2013, 73, 7156-7160.	0.9	7
57	It Is Not Always Necessary to Do Axillary Dissection for T1 and T2 Breast Cancerâ€”Reply to Point. Cancer Research, 2013, 73, 7155-7155.	0.9	1
58	Pediatric melanoma: Analysis of an international registry. Cancer, 2013, 119, 4012-4019.	4.1	71
59	The Interrelationship Between Cryoablation, the Immune Response and the Tumor Microenvironment: Stimulatory and Suppressive Effects. , 2013, , 77-107.		3
60	Recurrent STAT6 Mutations In Follicular Lymphoma. Blood, 2013, 122, 503-503.	1.4	1
61	Triple Receptorâ€”Negative Breast Cancer: Imaging and Clinical Characteristics. American Journal of Roentgenology, 2012, 199, 458-464.	2.2	88
62	Development of an intraoperative pathology consultation service at a free-standing ambulatory surgical center: clinical and economic impact for patients undergoing breast cancer surgery. American Journal of Surgery, 2012, 204, 66-77.	1.8	21
63	Validation of Statistical Predictive Models Meant to Select Melanoma Patients for Sentinel Lymph Node Biopsy. Annals of Surgical Oncology, 2012, 19, 287-293.	1.5	13
64	Intraoperative Frozen Section Analysis of Margins in Breast Conserving Surgery Significantly Decreases Reoperative Rates. American Journal of Clinical Pathology, 2012, 138, 657-669.	0.7	103
65	Sentinel lymph node biopsy for thin melanomaâ€”on. Journal of Surgical Oncology, 2012, 106, 217-218.	1.7	4
66	Is Duct Excision Still Necessary for All Cases of Suspicious Nipple Discharge?. Breast Journal, 2012, 18, 157-162.	1.0	45
67	Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer, 2012, 118, 1040-1047.	4.1	79
68	Is a level III dissection necessary for a positive sentinel lymph node in melanoma?. Journal of Surgical Oncology, 2012, 105, 225-228.	1.7	24
69	Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes. Blood, 2012, 120, 147-147.	1.4	1
70	Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nature Medicine, 2011, 17, 1646-1651.	30.7	301
71	Metastatic basal cell carcinoma from a small tumor with lymphatic invasion. Journal of the American Academy of Dermatology, 2011, 65, e16-e17.	1.2	4
72	Axillary Management. , 2011, , 217-239.		0

#	ARTICLE	IF	CITATIONS
73	Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles. International Journal of Proteomics, 2011, 2011, 1-8.	2.0	26
74	Clinical Utility of Serum Autoantibodies Detected by Protein Microarray in Melanoma. International Journal of Proteomics, 2011, 2011, 1-9.	2.0	9
75	Internet Use and Anxiety in People with Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery, 2011, 37, 1252-1259.	0.8	15
76	Surgical Considerations in Early-Stage Breast Cancer: Lessons Learned and Future Directions. Seminars in Radiation Oncology, 2011, 21, 10-19.	2.2	11
77	Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma. Annals of Surgical Oncology, 2011, 18, 3579-3585.	1.5	234
78	Membrane localization of insulin receptor substrate-2 (IRS-2) is associated with decreased overall survival in breast cancer. Breast Cancer Research and Treatment, 2011, 130, 759-772.	2.5	11
79	Cryoablation as a Replacement for Surgical Resection in Early Stage Breast Cancer. Current Breast Cancer Reports, 2011, 3, 109-116.	1.0	4
80	EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Modern Pathology, 2011, 24, 786-793.	5.5	66
81	Sentinel Lymph Node Biopsy for Melanoma: One Procedure but Many Questions. Archives of Dermatology, 2011, 147, 415.	1.4	1
82	Obesity and Angiolymphatic Invasion in Primary Breast Cancer. Annals of Surgical Oncology, 2010, 17, 752-759.	1.5	34
83	Rate of Freeze Alters the Immunologic Response After Cryoablation of Breast Cancer. Annals of Surgical Oncology, 2010, 17, 1187-1193.	1.5	78
84	Dermatofibrosarcoma Protuberans: How Wide Should We Resect?. Annals of Surgical Oncology, 2010, 17, 2112-2118.	1.5	134
85	Intratumoral delivery of encapsulated IL-12, IL-18 and TNF- α in a model of metastatic breast cancer. Breast Cancer Research and Treatment, 2010, 122, 325-336.	2.5	33
86	Phenotypic Heterogeneity among Tumorigenic Melanoma Cells from Patients that Is Reversible and Not Hierarchically Organized. Cancer Cell, 2010, 18, 510-523.	16.8	555
87	Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy: Pros and Cons. Surgical Oncology Clinics of North America, 2010, 19, 519-538.	1.5	24
88	Serum Autoantibody Profiling Using a Natural Glycoprotein Microarray for the Prognosis of Early Melanoma. Journal of Proteome Research, 2010, 9, 6044-6051.	3.7	23
89	Spline-based models for predictiveness curves and surfaces. Statistics and Its Interface, 2010, 3, 445-453.	0.3	2
90	Surgical Management of Primary Breast Cancer. , 2009, , 157-178.		0

#	ARTICLE	IF	CITATIONS
91	Melanoma: Do We Need a Hatchet or a Scalpel?. Archives of Dermatology, 2009, 145, 307-8.	1.4	3
92	Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?. Cancer, 2009, 115, 5752-5760.	4.1	91
93	Residual disease after re-excision lumpectomy for close margins. Journal of Surgical Oncology, 2009, 99, 99-103.	1.7	81
94	Determinants of Breast Conservation Rates: Reasons for Mastectomy at a Comprehensive Cancer Center. Breast Journal, 2009, 15, 34-40.	1.0	70
95	Prognostic Significance of a Positive Nonsentinel Lymph Node in Cutaneous Melanoma. Annals of Surgical Oncology, 2009, 16, 2978-2984.	1.5	54
96	Cryo-immunology: A review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology, 2009, 58, 1-11.	0.7	258
97	An Absence of Stromal Caveolin-1 Expression Predicts Early Tumor Recurrence and Poor Clinical Outcome in Human Breast Cancers. American Journal of Pathology, 2009, 174, 2023-2034.	3.8	307
98	Review of Evidence-Based Support for Pretreatment Imaging in Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 281-289.	4.9	15
99	Workup and Staging of the Breast Cancer Patient. , 2009, , 133-142.		1
100	Cryoablation for breast cancer: No need to turn a cold shoulder. Journal of Surgical Oncology, 2008, 97, 485-486.	1.7	13
101	State of the science 60th anniversary review. Cancer, 2008, 113, 1728-1743.	4.1	14
102	Do Micromorphometric Features of Metastatic Deposits Within Sentinel Nodes Predict Nonsentinel Lymph Node Involvement in Melanoma?. Annals of Surgical Oncology, 2008, 15, 2403-2411.	1.5	54
103	Axillary Staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence. Annals of Surgical Oncology, 2008, 15, 3252-3258.	1.5	38
104	Efficient tumour formation by single human melanoma cells. Nature, 2008, 456, 593-598.	27.8	1,674
105	Translational Research in Melanoma. Surgical Oncology Clinics of North America, 2008, 17, 391-419.	1.5	2
106	Epithelial and Stromal Cathepsin K and CXCL14 Expression in Breast Tumor Progression. Clinical Cancer Research, 2008, 14, 5357-5367.	7.0	90
107	Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer. Clinical Cancer Research, 2007, 13, 4092-4097.	7.0	17
108	Generation of a Tumor-specific Systemic Response After Intratumoral Injection of IL-12 and IL-18-loaded Poly(lactic Acid) Microspheres. Journal of Immunotherapy, 2007, 30, 808-816.	2.4	13

#	ARTICLE	IF	CITATIONS
109	The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. <i>Cancer</i> , 2007, 109, 100-108.	4.1	174
110	What is a sentinel node? Re-evaluating the 10% rule for sentinel lymph node biopsy in melanoma. <i>Journal of Surgical Oncology</i> , 2007, 95, 623-628.	1.7	28
111	Sentinel lymph node biopsy for breast cancer: How many nodes are enough?. <i>Journal of Surgical Oncology</i> , 2007, 96, 554-559.	1.7	67
112	Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. <i>Surgery</i> , 2007, 141, 728-735.	1.9	108
113	Synergistic effect of intratumoral IL-12 and TNF- α microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. <i>Surgery</i> , 2007, 142, 749-760.	1.9	39
114	Surgical Therapy of Cutaneous Melanoma. <i>Seminars in Oncology</i> , 2007, 34, 270-280.	2.2	14
115	Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation. <i>Annals of Surgical Oncology</i> , 2007, 14, 2946-2952.	1.5	145
116	Principles of Immunotherapy. , 2007, , 81-95.		0
117	The changing profile of esophageal cancer presentation and its implication for diagnosis. <i>Journal of the National Medical Association</i> , 2007, 99, 620-6.	0.8	24
118	Locoregional therapy of breast cancer: maximizing control, minimizing morbidity. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1281-1299.	2.4	2
119	ADAM15 Disintegrin Is Associated with Aggressive Prostate and Breast Cancer Disease. <i>Neoplasia</i> , 2006, 8, 319-329.	5.3	85
120	Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. <i>Cryobiology</i> , 2006, 53, 360-366.	0.7	73
121	The role of sentinel lymph node biopsy for melanoma: Evidence assessment. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 19-27.	1.2	63
122	Does the Method of Biopsy Affect the Incidence of Sentinel Lymph Node Metastases?. <i>Breast Journal</i> , 2006, 12, 53-57.	1.0	17
123	Melanoma Patients with Positive Sentinel Nodes Who Did Not Undergo Completion Lymphadenectomy: A Multi-Institutional Study. <i>Annals of Surgical Oncology</i> , 2006, 13, 809-816.	1.5	161
124	Clinicopathologic Features Associated With Having Four or More Metastatic Axillary Nodes in Breast Cancer Patients With a Positive Sentinel Lymph Node. <i>Annals of Surgical Oncology</i> , 2006, 13, 36-44.	1.5	55
125	Lymphatic Mapping and Sentinel Lymph Node Biopsy for Patients With Local Recurrence After Breast-Conservation Therapy. <i>Annals of Surgical Oncology</i> , 2006, 13, 52-57.	1.5	58
126	Significance of Multiple Lymphatic Basin Drainage in Truncal Melanoma Patients Undergoing Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2006, 13, 1216-1223.	1.5	36

#	ARTICLE	IF	CITATIONS
127	Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ. <i>Cancer</i> , 2006, 106, 2113-2118.	4.1	19
128	Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. <i>Cancer</i> , 2006, 107, 2346-2351.	4.1	266
129	Neoadjuvant intratumoral cytokine-loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti-tumor immunity. <i>Journal of Surgical Oncology</i> , 2006, 94, 403-412.	1.7	23
130	Allogeneic and Autologous Melanoma Vaccines: Where Have We Been and Where Are We Going?. <i>Clinical Cancer Research</i> , 2006, 12, 2337s-2341s.	7.0	78
131	Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram?. <i>Annals of Surgical Oncology</i> , 2005, 12, 712-717.	1.5	19
132	Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy. <i>Annals of Surgical Oncology</i> , 2005, 12, 697-704.	1.5	84
133	Predictors of Nonsentinel Lymph Node Positivity in Patients with a Positive Sentinel Node for Melanoma. <i>Journal of the American College of Surgeons</i> , 2005, 201, 37-47.	0.5	122
134	Wide excision without radiation for desmoplastic melanoma. <i>Cancer</i> , 2005, 104, 1462-1467.	4.1	51
135	CTLA-4 blockade augments human T lymphocyte-mediated suppression of lung tumor xenografts in SCID mice. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 944-952.	4.2	18
136	Immunologic response to cryoablation of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 90, 97-104.	2.5	161
137	RhoC-GTPase is a Novel Tissue Biomarker Associated with Biologically Aggressive Carcinomas of the Breast. <i>Breast Cancer Research and Treatment</i> , 2005, 93, 101-110.	2.5	101
138	Identification of GATA3 as a Breast Cancer Prognostic Marker by Global Gene Expression Meta-analysis. <i>Cancer Research</i> , 2005, 65, 11259-11264.	0.9	272
139	A Putative Role for Psoriasin in Breast Tumor Progression. <i>Cancer Research</i> , 2005, 65, 11326-11334.	0.9	79
140	Protein Kinase C μ Is a Predictive Biomarker of Aggressive Breast Cancer and a Validated Target for RNA Interference Anticancer Therapy. <i>Cancer Research</i> , 2005, 65, 8366-8371.	0.9	140
141	Patterns of Internet use and impact on patients with melanoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 779-785.	1.2	67
142	Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. <i>American Journal of Surgery</i> , 2005, 190, 543-550.	1.8	223
143	Immunologic approaches to breast cancer treatment. <i>Surgical Oncology Clinics of North America</i> , 2005, 14, 1-31.	1.5	8
144	Small (<2.0-cm) Breast Cancers: Mammographic and US Findings at US-guided Cryoablation—Initial Experience. <i>Radiology</i> , 2004, 233, 857-867.	7.3	77

#	ARTICLE	IF	CITATIONS
145	Intratumoral IL-12 and TNF- α -Loaded Microspheres Lead To Regression of Breast Cancer and Systemic Antitumor Immunity. <i>Annals of Surgical Oncology</i> , 2004, 11, 147-156.	1.5	94
146	Cryoablation of Early-Stage Breast Cancer: Work-in-Progress Report of a Multi-Institutional Trial. <i>Annals of Surgical Oncology</i> , 2004, 11, 542-549.	1.5	183
147	A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model. <i>Clinical and Experimental Metastasis</i> , 2004, 21, 363-369.	3.3	13
148	Current state of treatment for primary cutaneous melanoma. <i>Clinical and Experimental Medicine</i> , 2004, 4, 65-77.	3.6	13
149	Mitotic Rate and Younger Age Are Predictors of Sentinel Lymph Node Positivity: Lessons Learned From the Generation of a Probabilistic Model. <i>Annals of Surgical Oncology</i> , 2004, 11, 247-258.	1.5	296
150	Melanoma Vaccines. <i>American Journal of Cancer</i> , 2004, 3, 377-386.	0.4	0
151	Mastectomy and concomitant sentinel lymph node biopsy for invasive breast cancer. <i>American Journal of Surgery</i> , 2004, 187, 673-678.	1.8	9
152	Point: Interferon- α for Adjuvant Therapy for Melanoma Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2004, 2, 61-68.	4.9	5
153	Melanoma: Adjuvant therapy and other treatment options. <i>Current Treatment Options in Oncology</i> , 2003, 4, 187-199.	3.0	34
154	Is there a role for sentinel lymph node biopsy in the management of sarcoma?. <i>Surgical Oncology</i> , 2003, 12, 201-206.	1.6	72
155	Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. <i>Cancer</i> , 2003, 98, 2307-2315.	4.1	145
156	Is There a Role for Adjuvant High-Dose Interferon- γ in the Management of Melanoma?. <i>Drugs</i> , 2003, 63, 1053-1058.	10.9	11
157	Sentinel node biopsy prior to neoadjuvant chemotherapy. <i>American Journal of Surgery</i> , 2003, 186, 102-105.	1.8	113
158	Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma. <i>Oncologist</i> , 2003, 8, 451-458.	3.7	69
159	EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11606-11611.	7.1	1,482
160	Tumor Vaccines. <i>American Journal of Clinical Dermatology</i> , 2002, 3, 609-616.	6.7	12
161	Melanoma Vaccines: Breakthrough or Bust?. <i>Cancer Investigation</i> , 2002, 20, 1114-1116.	1.3	4
162	Esophageal resection for carcinoma in patients older than 70 years. <i>Annals of Surgical Oncology</i> , 2002, 9, 210-214.	1.5	78

#	ARTICLE	IF	CITATIONS
163	Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. <i>Cancer Research</i> , 2002, 62, 7254-63.	0.9	95
164	Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. <i>Surgery</i> , 2001, 130, 470-478.	1.9	29
165	In-Situ Ablation of Breast Cancer. <i>Breast Disease</i> , 2001, 12, 131-140.	0.8	12
166	Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 425-428.	1.3	33
167	Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. <i>Journal of Surgical Oncology</i> , 2001, 77, 243-246.	1.7	32
168	Alveolar Soft Part Sarcoma Metastatic to Small Bowel Mucosa Causing Polyposis and Intussuseption. <i>Sarcoma</i> , 2001, 5, 133-137.	1.3	4
169	An in-situ neoadjuvant vaccination with IL-12 and GM-CSF in biodegradable microspheres with systemic IL-2 provides protection against metastatic disease.. <i>Journal of the American College of Surgeons</i> , 2000, 191, S19-S20.	0.5	1
170	Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. <i>Journal of Immunological Methods</i> , 2000, 233, 57-65.	1.4	22
171	CD40 expression on human lung cancer correlates with metastatic spread. <i>Cancer Immunology, Immunotherapy</i> , 2000, 49, 101-108.	4.2	50
172	Evolution of sentinel lymph node biopsy for melanoma at a National Cancer Institute-designated cancer center. <i>Surgery</i> , 2000, 128, 556-563.	1.9	38
173	Principles of chronic venous access: recommendations based on the Roswell Park experience. <i>Surgical Oncology</i> , 1997, 6, 171-177.	1.6	7
174	Fine structure of zonal changes in experimental Nd:YAG laser-induced interstitial hyperthermia. <i>Lasers in Surgery and Medicine</i> , 1993, 13, 234-241.	2.1	105
175	A Weighted Sample Framework to Incorporate External Calculators for Risk Modeling. <i>Statistics in Biosciences</i> , 0, , 1.	1.2	0